David Assis, MD
Education
MD: Jefferson Medical College (2005)
BS: Messiah College (2001)
Fellowship: Yale University School of Medicine (2012 - 2013)
Chief Residency: Thomas Jefferson University Hospital (2009)
Residency: Thomas Jefferson University Hospital (2008)
Internship: Thomas Jefferson University Hospital (2006)
Professional Affiliations
Honors & Recognition
- Rising Professional AwardAmerican Liver Foundation - Connecticut Chapter (2016)
- 2014 Kushlan Junior Faculty AwardYale Section of Digestive Diseases (2014)
Professional Service
- American Association for Study of Liver Diseases (2016) Secretary of the Special Interest Group in Cholestatic and Biliary Disease.
- International Primary Sclerosing Cholangitis Study Group (2016) Co-leader of the Working Group on Clinical Trial Design.
- North American Consortium for Autoimmune Liver Disease (2014) Steering Committee member of the Consortium, which is consists of a group of investigators from multiple academic medical centers throughout the United States and Canada who are committed to open collaboration to improve the study and treatment of patients with autoimmune liver diseases.
- American Liver Foundation - Connecticut Chapter (2014) Board Member of Connecticut Chapter of the American Liver Foundation.
Certifications
AB of Internal Medicine, Internal Medicine (2008)
AB of Internal Medicine, Gastroenterology (2012)
AB of Internal Medicine, Transpant Hepatology (2014, recertified: 2015)
Dr. David N. Assis is a hepatologist at Yale who specializes in autoimmune liver diseases such as autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis. As co-director of the Yale Autoimmune and Cholestatic Liver Diseases Program, he also treats liver and digestive complications related to cystic fibrosis, providing patients with both cutting-edge care and compassionate support throughout their medical journey.
An assistant professor of medicine at Yale School of Medicine, Dr. Assis is dedicated to researching the causes and treatments of rare autoimmune liver conditions. He recieved the Kushlan Junior Faculty Award amongst other recognition for this work and plays an active role in national and international liver disease research groups.
Dr. Assis remains hopeful about the future of liver disease treatment, contributing to progress through both clinical care and research. He serves on advisory committees for several organizations and continues to lead efforts aimed at developing innovative therapies for these complex conditions.
